N@N

ROSG, OWW, MAKO, TPI, OMPI, GENT Are Seasonally Ripe To Go Down In the Next Five Weeks

April 15, 2013 / M2 PRESSWIRE / BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Rosetta Genomics Ltd (NASDAQ:ROSG), ORBITZ WORLDWIDE, INCORPORATION. (NYSE:OWW), MAKO Surgical Corp (NASDAQ:MAKO), Tenth Power Technologies Corp (AMEX:TPI), Obagi Medical Products Inc (NASDAQ:OMPI), Gentium SpA (NASDAQ:GENT) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: http://www.squeezetrigger.com/services/strat/mh.php

The following stocks are expected to go Down:

  Symbol  Company                          Expected Return  Odds                 By The Following Date
  ROSG    Rosetta Genomics Ltd             -8.35%           100.00% (6 of 6)     Wednesday, April 24th 2013
  OWW     ORBITZ WORLDWIDE, INCORPORATION.  -3.62%           100.00% (5 of 5)     Monday, April 22nd 2013
  MAKO    MAKO Surgical Corp               -0.92%           100.00% (5 of 5)     Wednesday, April 17th 2013
  TPI     Tenth Power Technologies Corp    -3.44%           100.00% (5 of 5)     Monday, April 29th 2013
  OMPI    Obagi Medical Products Inc       -5.04%           66.67% (4 of 6)      Wednesday, April 17th 2013
  GENT    Gentium SpA                      -4.59%           85.71% (6 of 7)      Friday, April 19th 2013

Rosetta Genomics Ltd (NASDAQ:ROSG) - Rosetta Genomics Ltd. develops and commercializes a range of microRNA-based diagnostic tools. MicroRNAs are a group of genes that are produced using instructions encoded in DNA. The company offers diagnostic tests, including miRview mets for identification of the primary site of metastatic cancer; miRview mets2, a microarray-based test to identify 42 tumor types that include carcinomas, soft tissue tumors, lymphoma, and other malignancies; miRview squamous to differentiate squamous from non-squamous non-small cell lung cancer; miRview meso to differentiate mesothelioma to differentiate mesothelioma, a cancer connected to asbestos exposure and other risk factors, from other carcinomas in the lung and pleura; and miRview lung, a lung cancer classification test for cytology samples. It also has various tests under development consisting of miRview kidney for differentiating four histological types of renal or kidney tumors, as well as body fluid based diagnostic tests for heart failure, a clinical syndrome resulting from structural or functional cardiac disorder. The company distributes its products primarily in Australia, Canada, Greece, India, Israel, New Zealand, Qatar, Saudi Arabia, Singapore, Turkey, and the United Arab Emirates. Rosetta Genomics Ltd. was founded in 2000 and is headquartered in Rehovot, Israel..

ORBITZ WORLDWIDE, INCORPORATION. (NYSE:OWW) - Orbitz Worldwide, Inc. operates as an online travel company worldwide. It enables leisure and business travelers to search for and book a range of travel products and services. The company offers various products and services comprising air travel, hotels, vacation packages, car rentals, cruises, travel insurance, as well as destination services, such as ground transportation, event tickets, and tours. Its brand portfolio includes Orbitz, CheapTickets, The Away Network, and Orbitz for Business in the United States; ebookers in Europe; and HotelClub and RatesToGo internationally. Orbitz Worldwide, Inc. also licenses its technology and business services to third parties, such as airlines and hotel partners and provides them various private label solutions, including building and hosting of custom Websites and supplying content feeds to partners' Websites. The company was founded in 2000 and is headquartered in Chicago, Illinois. Orbitz Worldwide, Inc. is a subsidiary of Travelport Limited..

MAKO Surgical Corp (NASDAQ:MAKO) - MAKO Surgical Corp., a medical device company, markets its advanced robotic arm solution and orthopedic implants for orthopedic procedures in the United States and internationally. The company offers MAKOplasty, a restorative surgical solution that enables orthopedic surgeons to treat patient specific osteoarthritic disease. It also provides robotic arm interactive orthopedic system (RIO) consisting of a tactile robotic arm utilizing an integrated bone cutting instrument; and a patient specific visualization component, which offers pre-operative and intra-operative guidance to the orthopedic surgeon, enabling tissue sparing bone removal, and accurate implant insertion and alignment. The company s MAKOplasty partial knee arthroplasty solution enables resurfacing of one or two specific diseased compartments of the joint, preserving more soft tissue and healthy bone of the knee; and MAKOplasty Total Hip Arthroplasty, a surgical solution that enables orthopedic surgeons to perform total hip arthroplasty. In addition, it offers tactile guidance system, which allows orthopedic surgeons to treat degenerative knee osteoarthritis from early-stage unicompartmental degeneration through mid-stage multicompartmental degeneration with a modular knee implant system; and RESTORIS family of implants for use in single and bicompartmental knee resurfacing procedures. The company markets its products through direct sales force, as well as through independent orthopedic product agents and distributors. MAKO Surgical Corp. was founded in 2004 and is headquartered in Fort Lauderdale, Florida..

Tenth Power Technologies Corp (AMEX:TPI) - Tianyin Pharmaceutical Co., Inc., through its subsidiary, Chengdu Tianyin Pharmaceutical Co., Ltd., engages in the development, manufacture, marketing, and sale of biopharmaceutical medicines, branded generics, modernized traditional Chinese medicines, and other pharmaceuticals in the People s Republic of China. It manufactures a portfolio of 58 products for use in the therapeutic areas of internal medicines, gynecology, hepatology, otolaryngology, gastroenterology, neurology, orthopedics, and urology. Tianyin Pharmaceutical Co., Inc. sells its products through regional distributors, as well as directly to the hospitals, clinics, and pharmacies. The company was founded in 1994 and is based in Chengdu, the People s Republic of China..

Obagi Medical Products Inc (NASDAQ:OMPI) - Obagi Medical Products, Inc., a specialty pharmaceutical company, develops, markets, and sells topical aesthetic and therapeutic prescription skin care systems. It offers Obagi Nu-Derm System, including prescription and OTC drugs that are used for the treatment of fine lines, wrinkles, acne, photo damage, hyperpigmentation, melasma, laxity, and skin sallowness; Obagi Condition and Enhance Systems that are used before and after surgical and non-surgical cosmetic procedures; Obagi-C Rx System comprises Vitamin C with 4% hydroquinone system to treat skin conditions resulting from sun damage and the oxidative damage of free radicals; and Professional-C products consisting of Vitamin C serums for the treatment of antioxidant protection, fine lines, wrinkles, and hyperpigmentation. The company also provides ELASTIderm Eye and D colletage, which increases the elasticity and skin tone of eyes, face, neckline, and chest; ELASTILash Eyelash Solution that enhances the appearance of thickness and fullness of eyelashes; CLENZIderm M.D. Systems and Tretinoin for treating acne; and Obagi Rosaclear System used for the treatment of rosacea. In addition, it offers Refissa and Blue Peel RADIANCE used for the treatment of fine facial lines, hyperpigmentation, and tactile roughness; Metronidazole used for the treatment of rosacea; Obagi Blue Peel Essential Kit used for the treatment of fine lines, wrinkles, and hyperpigmentation. Further, the company licenses non-prescription product concepts under the Obagi trademark to a Japanese-based pharmaceutical company for sale through consumer distribution channels in Japan. Obagi Medical Products, Inc. sells its products through sales force and distribution partners in the United States, North and Central America, Europe, the Middle East, and Asia to dermatologists, plastic surgeons, and other physicians that are focused on aesthetic and therapeutic skin care. The company was founded in 1988 and is headquartered in Long Beach, California..

Gentium SpA (NASDAQ:GENT) - Gentium S.p.A., a biopharmaceutical company, engages in the research and development of drugs derived from DNA and DNA molecules. It focuses on the development and manufacture of its primary product candidate, defibrotide, an investigational drug based on a mixture of single-stranded and double-stranded DNA extracted from pig intestines. The company develops defibrotide for the treatment and prevention of hepatic veno-occlusive disease (VOD), a condition in which veins in the liver are blocked as a result of cancer treatments, such as chemotherapy or radiation treatments that are administered prior to stem cell transplantation. It has completed a Phase III clinical trial of defibrotide for the treatment of severe VOD in the United States, Canada, and Israel; and a Phase II/III pediatric trial in Europe for the prevention of VOD. It also develops and sells sulglicotide, an active pharmaceutical ingredient (API) developed from swine duodenum for ulcer healing and gastrointestinal protection; and urokinase, an API made from human urine to dissolve fibrin clots. The company was formerly known as Pharma Research S.r.L. and changed its name to Gentium S.p.A. in July 2001. Gentium S.p.A. was founded in 1993 and is headquartered in Villa Guardia, Italy..

SqueezeTrigger.com has built a massive database that collects, analyzes and publishes multiple proprietary trading strategies that predict price moves in stocks, commodities and currencies. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of each of the strategies highlighted. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com

www.squeezetrigger.com monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO.

INVESTMENTS & TRADING

SqueezeTrigger -- 25 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

About SQUEEZETRIGGER.COM

WWW.SQUEEZETRIGGER.COM is a service designed to help bonafide shareholders of publicly traded US companies fight short selling. SqueezeTrigger.com has built a proprietary database that uses Threshold list feeds and short sale time and sale data from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short trades.

SQUEEZETRIGGER.COM has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2.5 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha'a"s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.

All material herein was prepared by SQUEEZETRIGGER.COM, based upon information believed to be reliable. The information contained herein is not guaranteed by SQUEEZETRIGGER.COM to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion.

Occassionally companies pay $995.00 to purchase data for information provided in reports issued by BUYINS.NET, a company affiliated with SQUEEZETRIGGER.COM. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SQUEEZETRIGGER.COM is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. SQUEEZETRIGGER.COM will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

SQUEEZETRIGGER.COM and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of SQUEEZETRIGGER.COM, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.

By visiting SQUEEZETRIGGER.COM or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. Global Automated Trading Systems, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to SQUEEZETRIGGER.COM and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State.

Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. SQUEEZETRIGGER.COM does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. SQUEEZETRIGGER.COM places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.

Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SQUEEZETRIGGER.COM undertakes no obligation to update such statements.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.

Contact: Thomas Ronk, CEO www.squeezetrigger.com +1-800-715-9999 Tom@squeezetrigger.com

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641